# Phase 8 — Final Assembly

## Deliverable Index

| Deliverable | Location | Covers |
|---|---|---|
| Product Proposal | `../MedGuardian_AI_Product_Proposal.docx` | Full 13-section proposal — opportunity, segmentation, strategy, UX, RICE, metrics, data, risk, ethics, roadmap, monetization, Specialty Pharma Extension |
| MVP 1 Specification | `../MVP1_Specification.docx` | Strict Phase 1 scope, acceptance criteria, regulatory posture |
| MVP 1 prototype | `../mvp1/` | Runnable, tested, zero-AI-dependency Phase 1 build |
| Real FDA interaction-text fetcher | `../openfda_interactions_fetcher.py`, `../data/openfda_interaction_warnings.csv` | Cached, real openFDA drug-label "Drug Interactions" text — reference context, not fabricated pairwise data |
| Full-vision demo | `../app.py`, `../ai_engine.py`, `../mock_data.py` | The complete product vision, including GenAI copilot, Physician View, Pharma Program Insights |
| Presentation — Code/Architecture Review | `../MedGuardian_AI_Prototype_Review.pptx` | Reusability, consumers, AI touchpoints, code-review action points |
| Presentation — AI Capabilities & Reuse | `../MedGuardian_AI_Capabilities_Reuse.pptx` | Business-facing case for why the underlying AI pattern is reusable |
| Presentation — Full Product Overview | `../MedGuardian_AI_Product_Overview_Slides.pptx` | 21-slide deck covering every proposal section, including regulatory positioning and the Specialty Pharma Extension |
| Logo assets | `../medguardian_logo_full.png`, `../medguardian_logo_icon.png` | Brand mark in the Sandoz blue palette |
| Phase docs | `./` (this folder) | This phase-by-phase breakdown |

## How the Pieces Fit Together

1. **The proposal (docx)** is the source of truth — every number, threshold, and claim elsewhere traces back to one of its sections.
2. **MVP 1 (spec + code)** is a strict subset of the proposal's own Phase 1 definition (Section 11, Section 6 P0 items) — not a separate vision, a disciplined trim of the same one.
3. **The full-vision demo** shows where the product goes *after* MVP 1 graduates — it deliberately includes features the RICE table marks P1/P2, so it should never be mistaken for what ships first.
4. **The decks** translate the same underlying facts for three different audiences: an engineering/code review, a business-capability pitch, and a full academic/investor walkthrough.

## What Changed Across Iterations (Traceable Decisions)

- The original proposal was extended with **Section 13 (Specialty Pharma Extension)** after identifying that a physician/pharma data loop was the highest-leverage unaddressed gap — not present in the first draft.
- **Section 9.7 (Regulatory Positioning & Timeline)** and the "Why Isn't This Already Solved?" framing were added directly in response to a professor's critique that the value proposition and approval timeline weren't explicit enough — both are now first-class, citable sections rather than implied.
- **MVP 1 was rebuilt twice**: first as a single-file trim of the full app, then restructured into a config-driven, modular, tested codebase (`src/` / `dashboards/` / `tests/`) once a stronger structural reference was reviewed — see `05_AI_Collaboration_Log.md` for the full account of that iteration.

## Known Gaps (Stated Honestly, Not Hidden)

- No live DrugBank license — interaction *pairs* remain an illustrative reference set even though drug *identity* is now real FDA data.
- No authentication, encryption, or persistent database in either the MVP 1 or full-vision codebases — required before any real patient data is used, and already tracked in the risk register.
- `06_Individual_Contribution_Statement.md` is a template, not a completed statement — it must be filled in by the actual project team.
